THE ARISING · Markets & Strategy · Long reads
C2N, Cambridge Cognition and a New Alzheimer's Trust Bundle UK Dementia Testing Into One Pathway
The UK partnership links a blood test, a digital cognitive assessment and imaging infrastructure. It is an organized service, not yet proof that it shortens the road to diagnosis.
Three organizations have joined to pull several parts of Alzheimer's assessment into a single UK pathway. The move bundles a blood test, a digital cognitive test and scanning infrastructure, so a patient can move through them as one route rather than several disconnected steps.
For a reader watching the longevity economy, the interesting question is not the announcement. It is whether bundling actually lowers the time to diagnosis.
Our research desk flagged a C2N Diagnostics partnership combining blood testing and cognitive assessment in the UK. We confirmed it against the original announcement, dated September 21, 2026.
The partners are C2N Diagnostics, Cambridge Cognition and The Alzheimer's Trust, a newly formed subsidiary of The Cancer Screening Trust. The pathway combines C2N's MHRA-registered PrecivityAD2 blood test, Cambridge Cognition's CANTAB Pathway digital cognitive assessments, and The Alzheimer's Trust's national phlebotomy and MRI infrastructure. UK clinicians can now order the blood test and the cognitive test through the Trust.
The announcement is real and the components are established products. The business development is the combination itself, not a new clinical result. It does not report a trial comparing this pathway against existing care.
The partners cite supporting evidence for the underlying tests. In a Swedish primary-care study, a digital cognitive test plus a blood biomarker reached about 90 percent accuracy versus roughly 70 percent for standard GP care. A JAMA study of more than 1,200 patients reported high negative and positive predictive values for PrecivityAD2. Those numbers describe the tests, not this bundled service.
Diagnosis in UK dementia care is slow: the partners cite an average of about 3.5 years from first symptoms. A route that reliably compresses that delay would be valuable, and it signals where private, organized longevity services are heading. Facts and context only here, not investment guidance. Not financial advice.
The most interesting question stays open: will the partnership actually shorten the road to diagnosis and improve care? The announcement gives no patient numbers, no waiting-time results and no comparison with current care. It also discloses no pricing or funding figures.
For now, this is an organized effort to arrange diagnostic services around a shared pathway. Evidence of practical benefit will require results beyond the announcement.
• Any published waiting-time or accuracy data from the pathway itself, not just its component tests. • Pricing, funding and how widely UK clinicians adopt it. • Whether the NHS integrates or runs its own comparison against this private route.
Claim What We Found Tier
C2N, Cambridge Cognition and a New Alzheimer's Trust Bundle UK Dementia Testing Into One Pathway Refiner Stocks Have Doubled in 2026 as the World Runs Short of Diesel